Cellectar Biosciences (CLRB) Q3 2024 earnings summary

Executive summary

• CLOVER WaM pivotal study in WM showed a 56.4% major response rate, 80% overall response, and 98.2% clinical benefit, supporting iopofosine I 131 as a potential first- and best-in-class therapy; NDA submission planned for late Q1 or Q2 2025.

• Lead asset iopofosine I 131 is in pivotal and ongoing trials for hematologic and pediatric cancers, with multiple regulatory designations (Fast Track, Orphan Drug, Rare Pediatric Disease) in the US and EU.

• Commercial readiness is advancing, focusing on radiotherapy-capable centers and a scalable sales model, with expanded collaborations and supply chain agreements.

• Expansion plans include additional indications in indolent lymphomas, solid tumors, and pediatric cancers, leveraging a robust radiotherapeutic pipeline.

• Ongoing development of additional PDC-based therapies and collaborations to expand the pipeline and generate near-term capital.

Financial highlights

• Cash and equivalents at September 30, 2024, were $34.3 million, up from $9.6 million at year-end 2023, bolstered by $17.5–$19.4 million net proceeds from warrant exercises.

• Cash runway expected into Q2 2025; up to $73.3 million potentially available from future milestone-based warrant exercises.

• Q3 2024 R&D expenses were $5.5 million (down from $7.0 million YoY); G&A expenses rose to $7.8 million (from $2.4 million YoY) due to commercialization prep.

• Net loss for Q3 2024 was $14.7 million, or $0.37 per basic share, compared to $17.5 million, or $1.55 per share, in Q3 2023.

• Financing activities in the nine months ended September 30, 2024, provided $54.6 million, mainly from preferred stock and warrant exercises.

Outlook and guidance

• NDA submission for iopofosine I 131 in WM expected late Q1 or Q2 2025, with potential FDA approval and launch in H2 2025.

• Cash on hand plus warrant tranches expected to fund operations through launch, but interim financing likely required.

• Management expects continued operating losses and negative cash flow until product approval and commercialization.

• Confirmatory study design under discussion with FDA and EMA; not required to be ongoing at NDA submission.